This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Paul Pentel, MD; Mary Beth O'Connell, PharmD
Hennepin County Medical Center Minneapolis, Minn

JAMA. 1989;262(17):2386-2387.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

Blackburn et al¹ cite our data² as evidence of a controversy regarding the magnitude of effect of phenylpropanolamine (PPA) on blood pressure. We suggest that our data and those of others, including Blackburn et al, are in fact quite consistent; they support the hypothesis that PPA at usual therapeutic doses (25 mg immediate release or 75 mg sustained release) produces little increase in blood pressure but that the dose-response curve is steep. The effect of usual therapeutic doses of PPA on blood pressure of normal subjects has been well studied. Some studies, particularly those that did not measure blood pressure in the supine position, find no increase in blood pressure,³ whereas others note a small increase from 75 mg of sustained-release PPA (5 to 6 mm Hg)^1,4 or 25 mg of immediate-release PPA (3 mm Hg).¹ Slightly higher doses of PPA . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?